share_log

HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

Benzinga Real-time News ·  Jul 8, 2022 06:08

HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment